Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


27.08.2018

1 BMC Gastroenterol
1 Clin Infect Dis
3 Dig Dis Sci
2 Eur J Gastroenterol Hepatol
1 Gastroenterology
4 J Hepatol
1 J Infect Dis
1 J Interferon Cytokine Res
4 J Med Virol
7 J Viral Hepat
1 J Virol
4 PLoS One
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Gastroenterol

  1. PANG X, Li X, Mo Z, Huang J, et al
    IFI16 is involved in HBV-associated acute-on-chronic liver failure inflammation.
    BMC Gastroenterol. 2018;18:61.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  2. BUTT AA, Yan P, Lo Re V 3rd, Shaikh OS, et al
    Trends in Treatment Uptake and Provider Specialty for HCV Infection in the VA Healthcare System: Results from ERCHIVES.
    Clin Infect Dis. 2018 Aug 22. pii: 5077936. doi: 10.1093.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  3. ZHANG G, Yu X, Liu P, Huang X, et al
    Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis.
    Dig Dis Sci. 2018 Aug 23. pii: 10.1007/s10620-018-5252.
    PubMed     Text format     Abstract available

  4. AHN SH, Marcellin P, Ma X, Caruntu FA, et al
    Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
    Dig Dis Sci. 2018 Aug 22. pii: 10.1007/s10620-018-5251.
    PubMed     Text format     Abstract available

  5. MARSHALL MC, Herrera JL
    Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
    Dig Dis Sci. 2018 Aug 20. pii: 10.1007/s10620-018-5247.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  6. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Text format     Abstract available

  7. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Text format     Abstract available


    Gastroenterology

  8. BOYER A, Park SB, de Boer Y, Li Q, et al
    TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.
    Gastroenterology. 2018 Aug 22. pii: S0016-5085(18)34892.
    PubMed     Text format     Abstract available


    J Hepatol

  9. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Text format     Abstract available

  10. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Text format     Abstract available

  11. KO C, Chakraborty A, Chou WM, Hasreiter J, et al
    Hepatitis B virus (HBV) genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32294.
    PubMed     Text format     Abstract available

  12. ROSSI C, Butt Z, Wong S, Buxton J, et al
    Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32288.
    PubMed     Text format     Abstract available


    J Infect Dis

  13. ANKCORN M, Moreira F, Ijaz S, Symes A, et al
    Absence of persistent Hepatitis E virus infection in antibody-deficient patients is associated with the transfer of antigen neutralising antibodies from immunoglobulin products.
    J Infect Dis. 2018 Aug 18. pii: 5075995. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Interferon Cytokine Res

  14. ABD EL-MEGUID M, Dawood RM, Mokhles MA, El Awady MK, et al
    Extrahepatic Upregulation of Transforming Growth Factor Beta 2 in HCV Genotype 4-Induced Liver Fibrosis.
    J Interferon Cytokine Res. 2018;38:341-347.
    PubMed     Text format     Abstract available


    J Med Virol

  15. EL-HEFNY MA, Fouad SA, Hussein TD, Abdel-Hameed R, et al
    Circulating miRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25294.
    PubMed     Text format     Abstract available

  16. CASTRO VOL, Tejada-Strop A, Weis SMS, Stabile AC, et al
    Evidence of hepatitis E virus infections among persons who use crack cocaine from the Midwest region of Brazil.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25288.
    PubMed     Text format     Abstract available

  17. JORDIER F, Deligny ML, Barre R, Robert C, et al
    Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25290.
    PubMed     Text format     Abstract available

  18. ELBAZ T, Abdo M, Omar H, Hassan EA, et al
    Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    J Med Virol. 2018 Aug 23. doi: 10.1002/jmv.25287.
    PubMed     Text format     Abstract available


    J Viral Hepat

  19. GROC S, Abbate JL, Le Gal F, Gerber A, et al
    High Prevalence and Diversity of Hepatitis B and Hepatitis Delta Virus in Gabon.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12991.
    PubMed     Text format     Abstract available

  20. LIM SG, Phyo WW, Shah SR, Win KM, et al
    Findings from a large asian chronic hepatitis c real life study.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
    PubMed     Text format     Abstract available

  21. MACIAS J, Granados R, Tellez F, Merino D, et al
    Similar recovery of liver function after response to all oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12990.
    PubMed     Text format     Abstract available

  22. JONES H, Patel P, Sears D
    Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988.
    PubMed     Text format     Abstract available

  23. SAEED S, Moodie EE, Strumpf E, Gill J, et al
    Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in HIV/Hepatitis C Co-Infected Individuals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12985.
    PubMed     Text format     Abstract available

  24. PERPINAN E, Caro-Perez N, Garcia-Gonzalez N, Gregori J, et al
    Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12986.
    PubMed     Text format     Abstract available

  25. LAFFERTY L, Rance J, Grebely J, Lloyd AR, et al
    Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12987.
    PubMed     Text format     Abstract available


    J Virol

  26. XIE Q, Chen S, Tian R, Huang X, et al
    Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


    PLoS One

  27. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    PubMed     Text format     Abstract available

  28. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.
    PLoS One. 2018;13:e0202991.
    PubMed     Text format     Abstract available

  29. WHITMILL A, Kim S, Rojas V, Gulraiz F, et al
    Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.
    PLoS One. 2018;13:e0202524.
    PubMed     Text format     Abstract available

  30. AL MAHTAB M, Akbar SMF, Aguilar JC, Guillen G, et al
    Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
    PLoS One. 2018;13:e0201236.
    PubMed     Text format     Abstract available


    Virology

  31. ZHANG H, Qiao L, Luo G
    Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesis.
    Virology. 2018;524:1-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: